wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36515526-F3E51250-2063-4867-9E37-2CF454222B1F
Q36515526-F3E51250-2063-4867-9E37-2CF454222B1F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36515526-F3E51250-2063-4867-9E37-2CF454222B1F
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
P2860
Q36515526-F3E51250-2063-4867-9E37-2CF454222B1F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36515526-F3E51250-2063-4867-9E37-2CF454222B1F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
eb0a379a0ee910d2a38fbed8f334b174d4a45b5e
P2860
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.